$6.72-2.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $31.5M | $30.2M | +4.14% |
| Profit | $2.7M | $63.9M | -95.74% |
| Profit per share | $0.02 | $1.94 | -98.97% |
| Free Cash Flow | -$20.1M | -$14.7M | -36.36% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We have moved beyond planning ROBBIN to mobilizing investigators and activating sites around the world in preparation for patient enrollment,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Agenus Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Agenus Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From Agenus Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Actual
$31.5M
+4.1% y/y
-8.8% q/q
Guided
—
No guide given
Actual
$0.02
-99% y/y
Guided
—
No guide given
Actual
$11.4M
+1.0% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.